Appili Therapeutics Inc. (APLI.TO)
| Previous Close | 0.0400 |
| Open | 0.0450 |
| Bid | 0.0400 x N/A |
| Ask | 0.0450 x N/A |
| Day's Range | 0.0450 - 0.0450 |
| 52 Week Range | 0.0350 - 0.1250 |
| Volume | |
| Avg. Volume | 121,971 |
| Market Cap | 5.457M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1000 |
| Earnings Date | Feb 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.20 |
- Business Wire
Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
HALIFAX, Nova Scotia, March 20, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has entered into an amended and restated secured loan agreement (the "Amended Loan Agreement") with Long Zone Holdings Inc. ("LZH"), amending and restating the original secured loan agreement by and between Appili and LZH dated March 25, 2022 (the "Original Loan
- Business Wire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
HALIFAX, Nova Scotia, February 14, 2023--Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022.
- Business Wire
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
HALIFAX, Nova Scotia, February 08, 2023--Appili Therapeutics Inc. (TSX: APLI) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today, with its partner Saptalis Pharmaceuticals LLC ("Saptalis"), announced that the Food and Drug Administration ("FDA") accepted the ATI-1501 New Drug Application ("NDA"). ATI-1501 is Appili’s liquid oral reformulation of the antibiotic metronidazole, which has been licensed to Saptalis. The F
